An additional press release indicates that Thermo Fisher expanded its suite of Orbitrap mass spectrometry platforms, AI-enabled software, and integrated workflows at the conference, mentioning a total of three new platforms . However, the specific identity of a third platform, often described in broader question sets as the "Orbitrap Exploris GC S," was not clearly named or detailed in the available evidence as a distinct ASMS 2026 launch. The provided materials instead confirm the existing broader Orbitrap Exploris GC Series product family .

Orbitrap Tribrid Apex: The Multi-Purpose Research Powerhouse

The Orbitrap Tribrid Apex is positioned as a versatile, high-end system designed to consolidate multiple research workflows onto a single instrument .

• Target Applications: The instrument is explicitly built for multiomics, structural biology, biopharma characterization, and small-molecule analysis . Product-specific pages further detail dedicated configurations for MultiOmics and Structural Biology research .
• Performance Claims: The key headline specification is a five times greater sensitivity compared to previous-generation instruments . The company also states the Apex can deliver up to 100% sequence coverage in a single experiment and generate results up to four times faster .
• Key Technologies: To achieve this performance, the Tribrid Apex uses enhanced ion parallelization, flexible MSⁿ workflows, and incorporates the first commercial IR-based laser for more efficient IR-assisted fragmentation (IR-ETD) and improved desolvation of native proteins . It is built on a field-upgradeable architecture and will be available in four application-specific editions .

Orbitrap Excedion: Purpose-Built for Drug Development

The Orbitrap Excedion is the second confirmed major platform, designed specifically for the rigorous demands of pharmaceutical development.

• Target Applications: The Excedion is designed to help pharmaceutical scientists reduce risk in increasingly complex drug development pipelines . The conference materials highlight its use for complex biologics, including GLP-1 therapies, oligonucleotides, and antibody-drug conjugates .
• Performance Claims: The primary performance differentiator is the ability to detect three to five times more compounds in complex samples . This enhanced detection is framed as a way to provide more comprehensive, regulatory-ready data by reducing analytical blind spots .
• Key Technologies: Product details for the related Excedion Pro model, which provides the best available technical context, describe a high-field Orbitrap analyzer that delivers up to 70 Hz MS² scan rates and an extended mass range up to m/z 12,000, enabling robust intact and native analyses .

The Third Platform and the "Orbitrap Exploris GC S" Question

A broader ASMS 2026 announcement mentions the introduction of three new Orbitrap platforms . The existing evidence, however, strongly supports the existing Orbitrap Exploris GC Series as a family of high-resolution GC-MS systems, rather than documenting a specific new "Orbitrap Exploris GC S" variant launched at the event .

The Exploris GC product line is intended for applied markets and environmental testing, offering configurations as either GC-MS or GC-MS/MS systems with a resolution up to 60,000 at m/z 200 . It is important to note that the connection between this established product line and a newly named "GC S" variant is not supported by the source materials referenced from the conference.

AI-Enabled Software and the MSAID and Proteinaceous Acquisitions

While a press release headline states that Thermo Fisher expanded its "AI-enabled software and integrated workflows" at ASMS 2026 , the available source snippets do not provide verifiable details on specific software product names, features, or end-to-end workflow demonstrations from the show floor . The role of the company's AI-driven software is generally described as helping scientists turn complex biology into actionable insights and handle the analytical demands of modern drug development .

Regarding the acquisitions of MSAID and Proteinaceous, the provided ASMS 2026 source snippets contain no explicit mention of these companies . Without direct confirmation from conference materials, it is not possible to verify from this evidence whether either acquisition was formally highlighted or integrated into the ASMS 2026 announcements. Any specific claims about their role in Thermo Fisher's proteomics software ecosystem at this event would require additional sourcing beyond the materials listed here.

Summary of Key Differences

The following table summarizes the differences between the two confirmed platforms based on available evidence:

The core distinction is clear: the Tribrid Apex consolidates broad, flexible capabilities for deep biological discovery, while the Excedion is honed for the high-stakes, specific workflows of pharmaceutical analysis. While the promise of deeper AI integration exists, the precise details of those tools remain the most significant gap in what was formally reported from the 2026 San Diego conference.

An additional press release indicates that Thermo Fisher expanded its suite of Orbitrap mass spectrometry platforms, AI-enabled software, and integrated workflows at the conference, mentioning a total of three new platforms . However, the specific identity of a third platform, often described in broader question sets as the "Orbitrap Exploris GC S," was not clearly named or detailed in the available evidence as a distinct ASMS 2026 launch. The provided materials instead confirm the existing broader Orbitrap Exploris GC Series product family .

Orbitrap Tribrid Apex: The Multi-Purpose Research Powerhouse

The Orbitrap Tribrid Apex is positioned as a versatile, high-end system designed to consolidate multiple research workflows onto a single instrument .

• Target Applications: The instrument is explicitly built for multiomics, structural biology, biopharma characterization, and small-molecule analysis . Product-specific pages further detail dedicated configurations for MultiOmics and Structural Biology research .
• Performance Claims: The key headline specification is a five times greater sensitivity compared to previous-generation instruments . The company also states the Apex can deliver up to 100% sequence coverage in a single experiment and generate results up to four times faster .
• Key Technologies: To achieve this performance, the Tribrid Apex uses enhanced ion parallelization, flexible MSⁿ workflows, and incorporates the first commercial IR-based laser for more efficient IR-assisted fragmentation (IR-ETD) and improved desolvation of native proteins . It is built on a field-upgradeable architecture and will be available in four application-specific editions .

Orbitrap Excedion: Purpose-Built for Drug Development

The Orbitrap Excedion is the second confirmed major platform, designed specifically for the rigorous demands of pharmaceutical development.

• Target Applications: The Excedion is designed to help pharmaceutical scientists reduce risk in increasingly complex drug development pipelines . The conference materials highlight its use for complex biologics, including GLP-1 therapies, oligonucleotides, and antibody-drug conjugates .
• Performance Claims: The primary performance differentiator is the ability to detect three to five times more compounds in complex samples . This enhanced detection is framed as a way to provide more comprehensive, regulatory-ready data by reducing analytical blind spots .
• Key Technologies: Product details for the related Excedion Pro model, which provides the best available technical context, describe a high-field Orbitrap analyzer that delivers up to 70 Hz MS² scan rates and an extended mass range up to m/z 12,000, enabling robust intact and native analyses .

The Third Platform and the "Orbitrap Exploris GC S" Question

A broader ASMS 2026 announcement mentions the introduction of three new Orbitrap platforms . The existing evidence, however, strongly supports the existing Orbitrap Exploris GC Series as a family of high-resolution GC-MS systems, rather than documenting a specific new "Orbitrap Exploris GC S" variant launched at the event .

The Exploris GC product line is intended for applied markets and environmental testing, offering configurations as either GC-MS or GC-MS/MS systems with a resolution up to 60,000 at m/z 200 . It is important to note that the connection between this established product line and a newly named "GC S" variant is not supported by the source materials referenced from the conference.

AI-Enabled Software and the MSAID and Proteinaceous Acquisitions

While a press release headline states that Thermo Fisher expanded its "AI-enabled software and integrated workflows" at ASMS 2026 , the available source snippets do not provide verifiable details on specific software product names, features, or end-to-end workflow demonstrations from the show floor . The role of the company's AI-driven software is generally described as helping scientists turn complex biology into actionable insights and handle the analytical demands of modern drug development .

Regarding the acquisitions of MSAID and Proteinaceous, the provided ASMS 2026 source snippets contain no explicit mention of these companies . Without direct confirmation from conference materials, it is not possible to verify from this evidence whether either acquisition was formally highlighted or integrated into the ASMS 2026 announcements. Any specific claims about their role in Thermo Fisher's proteomics software ecosystem at this event would require additional sourcing beyond the materials listed here.

Summary of Key Differences

The following table summarizes the differences between the two confirmed platforms based on available evidence:

The core distinction is clear: the Tribrid Apex consolidates broad, flexible capabilities for deep biological discovery, while the Excedion is honed for the high-stakes, specific workflows of pharmaceutical analysis. While the promise of deeper AI integration exists, the precise details of those tools remain the most significant gap in what was formally reported from the 2026 San Diego conference.